Centessa Pharmaceuticals Limited (CNTA): Price and Financial Metrics
CNTA Price/Volume Stats
Current price | $6.22 | 52-week high | $8.65 |
Prev. close | $6.36 | 52-week low | $3.00 |
Day low | $6.02 | Volume | 27,700 |
Day high | $6.40 | Avg. volume | 156,053 |
50-day MA | $6.80 | Dividend yield | N/A |
200-day MA | $4.96 | Market Cap | 605.85M |
CNTA Stock Price Chart Interactive Chart >
Centessa Pharmaceuticals Limited (CNTA) Company Bio
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Latest CNTA News From Around the Web
Below are the latest news stories about CENTESSA PHARMACEUTICALS PLC that investors may wish to consider to help them evaluate CNTA as an investment opportunity.
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's WhyCentessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies. |
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceBOSTON and LONDON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, including a fireside chat on Tuesday, September 12, 2023 at 4:15 p.m. ET. The live webcast of this event, as well as an archived recording, will be availa |
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep CongressOral presentation to include preclinical profile for ORX750, Centessa’s first orexin agonist development candidate for the treatment of narcolepsy and other sleep disordersBOSTON and LONDON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that preclinical data for ORX750, its first orexin agonist development candidate, will |
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, L |
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without InhibitorsEnrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of studyBOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-2 study of SerpinPC for the treatment of hemophilia B without inhibitors. The |
CNTA Price Returns
1-mo | -7.72% |
3-mo | 0.48% |
6-mo | 61.56% |
1-year | 33.19% |
3-year | N/A |
5-year | N/A |
YTD | 100.65% |
2022 | -72.47% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
Loading social stream, please wait...